E3 STRATEGIC CONSULTING GROUP for PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing and price controls, supply chain issues, pharmacy benefit managers transparency issues, intellectual property, trade, and employment issues, 340B program, generally; S. 1040, Drug Competition Enhancement Act; H.R. 1492, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program; H.R. 4317, PBM Reform Act of 2025; H.R. 5256, 340B ACCESS Act"; S. 3345, "PBM Price Transparency and Accountability Act"; S. 2658, Medication Affordability and Patent Integrity Act; S. 1414, Expedited Access to Biosimilars Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PATRICK FOLEY | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.